Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis

Archives of Disease in Childhood

Volumn 91, Issue 9, 2006, Pages 753-761

  Thornton, J ^a   Ashcroft, D M ^a   Mughal, M Z ^b   Elliott, R A ^a   O'Neill, T W ^a   Symmons, D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARACETAMOL;

BONE DENSITY; BONE DEVELOPMENT; BONE FRAGILITY; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; BONE DENSITY CONSERVATION AGENTS; CHILD; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS;

EID: 33748440973     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.093997     Document Type: Review

References (84)

1. Burnham JN, Weinstein R, Lewis JD, et al. Childhood onset arthritis is associated with an elevated risk of fracture. Abstract 157. American College of Rheumatology Annual Meeting, 2005.
2. Zak M, Hassager C, Lovell DJ, et al. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study. Arthritis Rheum 1999;42:790-8.
3. French AR, Mason T, Nelson AM, et al. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J Rheumatol 2002;29:1065-70.
4. Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5.
5. Kanis JA. Diagnosis of osteoporosis. Osteoporos Int 1997;7(suppl3):S108- 16.
6. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
7. Goulding A, Jones IE, Taylor RW, et al. More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures. J Bone Miner Res 2000;15:2011-18.
8. Haugen M, Lien G, Flato B, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum 2000;43:1504-10.
9. Kotaniemi A, Savolainen A, Kroger H, et al. Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 1999;28:19-26.
10. Rooney M, Davies UM, Reeve J, et al. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000;27:1073-81.
11. Perez MD, Abrams SA, Loddeke L, et al. Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy x-ray absorptiometry. J Rheumatol 2000;58:38-43.
12. Brik R, Keidar Z, Schapira D, et al. Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998;25:990-2.
13. Henderson G, Specker BL, Sierra RI, et al. Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000;43:531-40.
14. Kotaniemi A, Savolainen A, Kroger H, et al. Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 1999;28:19-26.
15. Stevenson M, Lloyd JM, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
16. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005;90:494-9.
17. Srivastava T, Alon US. The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003;162:735-51.
18. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. 4, 2nd edn. York: University of York, 2001.
19. Cimaz R, Gattorno M, Sormani MP, et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002;29:1786-92.
20. Rudge S, Hailwood S, Home A, et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005;44:813-18.
21. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000;43:1960-6.
22. Lepore L, Pennesi M, Barbi E, et al. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991;9(suppl 6):33-5.
23. Acott PD, Wong JA, Lang BA, et al. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005;20:368-73.
24. Noguera A, Ros JB, Pavia C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003;16:529-36.
25. Gandrud LM, Cheung JC, Daniels MW, et al. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol 2003;16:887-92.
26. Gatrinara M, Pontikaki I, Gerloni V, et al. Use of cyclic etidronate in patients with juvenile chronic rheumatic diseases receiving long term treatment with steroids. Ann Rheum Dis 2000;59:743-4.
27. Bardare M, Grassi A, Dell'Era L, et al. Alendronate in the treatment of osteoporosis in rheumatic diseases of childhood. Ann Rheum Dis 2000;59:742.
28. Falcini F, Trapani S, Ermini M, et al. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996;58:166-9.
29. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997;76:266-83.
30. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000;83:143-5.
31. Chlebna-Sokol D, Blaszczyk A, Rusinska A, et al. Treatment of osteoporosis and osteopenia in children-own experience. Przegl Lek 2003;60:5-11.
32. Fernandes JL, Viana SL, Rocha AL, et al. Biphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases Skeletal Radiol 2004;33:732-6.
33. Bayer M, Stepan J, Kutilek S. Alendronate in treatment of osteoporosis in childhood. Osteologicky Bulletin 2002;7:23-4.
34. Oliveri MB, Palermo R, Mautalen C, et al. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996;23:2152-5.
35. Rauch F, Plotkin H, Travers R, et al. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-92.
36. Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19:1779-86.
37. Zeirlin L, Rauch F, Plotkin H, et al. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111:1030-6.
38. Rauch F, Plotkin H, Zeitlin L, et al. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003;18:610-14.
39. Rauch F, Travers R, Plotkin H, et al. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta J Clin Invest 2002;110:1293-9.
40. Montpetit K, Plotkin H, Rauch F, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003;111:e601-3.
41. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003;33:226-9.
42. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
43. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86:356-64.
44. Arikoski P, Silverwood B, Tillmann V, et al. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004;34:539-46.
45. Robinson RF, Nahata MC, Hayes JR, et al. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 2004;24:195-7.
46. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 2004;17:1511-17.
47. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002;15:163-74.
48. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 2003;142:417-23.
49. Bin-Abbas BS, Al Ashwal AA, Al Zayed ZS, et al. Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta. Saudi Medical Journal 2004;25:1772-3.
50. Banerjee I, Shorthand GJ, Evans WD, et al. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 2002;87:562-3.
51. Dimeglio LA, Ford L, McClintock C, et al. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004;35:1038-45.
52. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50.
53. van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992;184:249-54.
54. Giraud F, Meunier PJ. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint, Bone, Spine: Revue du Rhumatisme 2002;69:486-90.
55. Folk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003;111:573-8.
56. Lee YS, Low SL, Lim LA, et al. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160:641-4.
57. Bishop NJ, Lanoue G, Chabot G, et al. Clinical and bone densitometric improvement after pamidronate infusion in children with severe osteogenesis imperfecta. J Bone Miner Res 1996;11:S251.
58. Huzjak N, Barisic I, Resic A, et al. Our experience in the treatment of osteogenesis imperfecta with bisphosphates. Paediatria Croatica 2002;46:55-9.
59. Fujiwara I, Ogawa E, Igarashi Y, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998;157:261-2.
60. Sumnik Z, Land C, Rieger-Wettengl G, et al. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis: a pilot study using radiographic morphometry. Horm Res 2004;61:137-42.
61. Munns CF, Rauch F, Mier RJ, et al. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004;35:231-4.
62. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87:64-8.
63. Gonzalez E, Pavia C, Ros J, et al. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;14:529-33.
64. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997;131:622-5.
65. Roldan EJA, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. J Pediatr Endocrinol Metab 1999;12:555-9.
66. Munns CF, Rauch F, Ward L, et al. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004;19:1742-5.
67. Guillot M, Eckart P, Desrosieres H, et al. Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report. Arch Pediatr 2001;8:172-5.
68. Chien YH, Chu SY, Hsu CC, et al. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002;25:593-5.
69. Devogelaer JP, Nagant de Deuxchaisnes C, Malghem J, et al. Cyclical intermittent therapy with APD in a child with osteogenesis imperfecta: a 3-year follow-up of 7 cycles. Evidence of fading away or the oldest radio-opaque bands. In: Christiansen C, Overgaard K, eds. Osfeoporosis. Aalborg: Handelstrykkeriet Aalborg ApS, 1990:1515-17.
70. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 1988;8:71-2.
71. Devogelaer JP, Malghem J, Maldague B, et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16:360-3.
72. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003;92:452-5.
73. Shaw NJ. Bisphosphonates in osteogenesis imperfecta. Arch Dis Child 1997;77:92-3.
74. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004;363:1427-31.
75. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, et al. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997;156:792-4.
76. Ashford RU, Dey A, Kayan K, et al. Oral clodronate as treatment of osteogenesis imperfecta. Arch Dis Child 2003;88:945.
77. Hogler W, Yap F, Little D, et al. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004;145:701-4.
78. Fewtrell MS, British Paediatric & Adolescent Bone Group. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child 2003;88:795-8.
79. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63.
80. Hoekman K, Papapoulos SE, Peters AC, et al. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 1985;61:952-6.
81. Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006;21:374-9.
82. Marini JC. Do bisphosphonates make children's bones better or brittle? N Engl J Med 2003;349:423-6.
83. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31.
84. Department of Health. National Service Framework for Children, Young People and Maternity Services. London: Department of Health, 2004.